Genfit S.A. (0QT6.IL)
| Previous close | 3.0810 |
| Open | 3.0540 |
| Bid | 3.0000 x 0 |
| Ask | 3.1520 x 0 |
| Day's range | 3.0540 - 3.0660 |
| 52-week range | 2.7800 - 4.7180 |
| Volume | |
| Avg. volume | 7,541 |
| Market cap | 153.232M |
| Beta (5Y monthly) | 1.22 |
| PE ratio (TTM) | 2.54 |
| EPS (TTM) | 1.2100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
GENFIT: May 25, 2022 Combined Shareholders Meeting results
Quorum of 25.16% on first convening; allowing approval of all the resolutions submitted by the Board of Directors Lille, France; Cambridge, MA; May 25, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the results of the Combined Shareholders Meeting which took place on May 25, 2022. The quorum on first convening amounted to 25.16% and shareholders approved all of the
- Globe Newswire
GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)
Cash and cash equivalents totaled €222.2 million as of March 31, 2022 Lille, France; Cambridge, MA; May 11, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its cash position as of March 31, 2022 and revenues for the first three months of 2022.Cash position As of March 31, 2022, the Company’s cash and cash equivalents amounted to €222.2 million compared with €108.9 mi
- Globe Newswire
GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022
Lille, France; Cambridge, MA; April 29, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the filing of its 2021 Universal Registration Document with the Autorité des marchés financiers (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission (SEC), as well as the availability of preparatory document
